Tue, Sep 16, 2014, 6:40 AM EDT - U.S. Markets open in 2 hrs 50 mins

Recent

% | $
Quotes you view appear here for quick access.

Catalyst Pharmaceutical Partners Inc. Message Board

  • pharma.heroooooo pharma.heroooooo Sep 11, 2013 7:02 PM Flag

    Analyst says Annual sales could hit $10 M // CPRX must pay royalties to BMRN & many others

     

    This brutally pumped scam will never make a penny because they burn almost $10 M per Quarter . Everyone with a brain should realize that this scam will never survive except if they diluting the hell out of this scam and thats what they already did in the past and still doing .

    --
    Firdapse hit the market in Europe in April 2010 and through the first nine months of this year registered sales of $10.8 million.

    BioMarin's $5 million investment in Catalyst will convert into Catalyst common stock at some time in the future, Catalyst said in a press release. Catalyst also will owe royalty payments to BioMarin as well as milestones and royalties to former Huxley shareholders and to an undisclosed third-party licensor of the Firdapse rights that are now sublicensed to Catalyst.

    Sentiment: Strong Sell

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
CPRX
3.15+0.06(+1.94%)Sep 15 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Avanir Pharmaceuticals, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT
21Vianet Group, Inc.
NasdaqGSMon, Sep 15, 2014 4:00 PM EDT